Xie Z - Search Results

1

Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling.

Guo Z, Xie Z, Shi H, Du W, Peng L, Han W, Duan F, Zhang X, Chen M, Duan J, Lin J, Chen X, Lizaso AA, Han-Zhang H, He J, Yin W. Guo Z, et al. Among authors: xie z. Thorac Cancer. 2019 Apr;10(4):823-831. doi: 10.1111/1759-7714.13006. Epub 2019 Feb 18. Thorac Cancer. 2019. PMID: 30779318 Free PMC article.

2

Extracranial abscopal effect induced by combining immunotherapy with brain radiotherapy in a patient with lung adenocarcinoma: A case report and literature review.

Lin X, Lu T, Xie Z, Qin Y, Liu M, Xie X, Li S, Zhou C. Lin X, et al. Among authors: xie x, xie z. Thorac Cancer. 2019 May;10(5):1272-1275. doi: 10.1111/1759-7714.13048. Epub 2019 Mar 30. Thorac Cancer. 2019. PMID: 30929314 Free PMC article. Review.

3

Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.

Zhao Y, Liu J, Cai X, Pan Z, Liu J, Yin W, Chen H, Xie Z, Liang H, Wang W, Guo Z, Zhao S, Liang W, He J. Zhao Y, et al. Among authors: xie z. BMJ. 2019 Oct 7;367:l5460. doi: 10.1136/bmj.l5460. BMJ. 2019. PMID: 31591158 Free PMC article.

4

A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung.

Xie Z, Liu L, Lin X, Xie X, Gu Y, Liu M, Zhang J, Ouyang M, Lizaso A, Zhang H, Feng W, Li B, Han-Zhang H, Chen S, Li S, Zhong N, Liu H, Zhou C, Qin Y. Xie Z, et al. Among authors: xie x. Mod Pathol. 2020 Apr;33(4):626-638. doi: 10.1038/s41379-019-0391-9. Epub 2019 Oct 28. Mod Pathol. 2020. PMID: 31659278 Free PMC article.

5

Presence of allele frequency heterogeneity defined by ctDNA profiling predicts unfavorable overall survival of NSCLC.

Liu Z, Xie Z, Zhao S, Ye D, Cai X, Cheng B, Li C, Xiong S, Li J, Liang H, Chen Z, Liang P, Liu J, He J, Liang W. Liu Z, et al. Among authors: xie z. Transl Lung Cancer Res. 2019 Dec;8(6):1045-1050. doi: 10.21037/tlcr.2019.12.10. Transl Lung Cancer Res. 2019. PMID: 32010581 Free PMC article.

6

The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303).

Jiang S, Liang H, Liu Z, Zhao S, Liu J, Xie Z, Wang W, Zhang Y, Han B, He J, Liang W. Jiang S, et al. Among authors: xie z. Oncologist. 2020 May;25(5):e870-e874. doi: 10.1634/theoncologist.2019-0838. Epub 2020 Feb 20. Oncologist. 2020. PMID: 32077550 Free PMC article. Clinical Trial.

7

A Modified Algorithm Adjusting Both High and Minor Allele Frequency Mutation to Redefine Blood-Based Tumor Mutational Burden (bTMB) for Optimal Prediction of Clinical Benefits From Immune Checkpoint Inhibitor Therapy.

Liu Z, Xie Z, Cai X, He J, Liang W. Liu Z, et al. Among authors: xie z. J Thorac Oncol. 2020 May;15(5):e69-e72. doi: 10.1016/j.jtho.2019.12.120. J Thorac Oncol. 2020. PMID: 32340679 Free article. No abstract available.

8

Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort.

Song Y, Hu C, Xie Z, Wu L, Zhu Z, Rao C, Liu L, Chen Y, Liang N, Chen J, Hu C, Yang N, Hu J, Zhao W, Tong G, Dong X, Zheng D, Jin M, Chen J, Huang M, He Y, Rosell R, Lippi G, Mino-Kenudson M, Han-Zhang H, Mao X, Zhang L, Liu H, Field JK, Chuai S, Ye J, Han Y, Lu S; Written on behalf of AME Lung Cancer Collaborative Group. Song Y, et al. Among authors: xie z. Transl Lung Cancer Res. 2020 Apr;9(2):269-279. doi: 10.21037/tlcr.2020.03.17. Transl Lung Cancer Res. 2020. PMID: 32420066 Free PMC article.

9

Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.

Xie Z, Gu Y, Xie X, Lin X, Ouyang M, Qin Y, Zhang J, Lizaso A, Chen S, Zhou C. Xie Z, et al. Among authors: xie x. Clin Lung Cancer. 2021 May;22(3):e390-e394. doi: 10.1016/j.cllc.2020.06.008. Epub 2020 Jun 11. Clin Lung Cancer. 2021. PMID: 32693944 Free article. No abstract available.

10

Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma.

Guo LH, Zhang MF, Zhang HL, Zhou JY, Cai XH, Long Y, Guo QS, Yang N, Zhao J, Xie ZH, Jiang B, Zhu Y, Fan Y, Xie CY, Hu Y, Yao Y, Jia J, Li XL, Cui JW, Sui XZ, Lin W, Cheng Y, Wang HJ, Wang CL, Zhao MF, Qiao GB, Peng LJ, Yang L, Chen GY, Cai KC, Xu XH, Zhang LM, Feng GS, Zhou JM, Wu GW, Dong XR, Wang LF, Zhang HM, Gao YJ, Jiang QY, Cang SD, Yang ZX, Song X, Liu XQ, Zhu B, Chen FX, Hu CH, Chen X, Wu YL, Zhou Q. Guo LH, et al. Front Oncol. 2020 Sep 15;10:1568. doi: 10.3389/fonc.2020.01568. eCollection 2020. Front Oncol. 2020. PMID: 33042801 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12,523 results

Search Page

Filters